The Wind Up – Watch News #335
Oris Divers Sixty-Five Chronograph 40mm | Image: Oris
Oris Divers Sixty-Five Chronograph 40mm
Brand: Oris
Oris Model: Divers Sixty-Five Chronograph 40mm
Divers Sixty-Five Chronograph 40mm Reference: Ref. 01 771 7791 4051-07 6 20 01
Ref. 01 771 7791 4051-07 6 20 01 Diameter: 40mm
40mm Thickness: 15.40mm
15.40mm Material : Stainless steel
: Stainless steel Movement: Oris Calibre 771
Oris Calibre 771 Power Reserve: 62 hours
62 hours Price: AUD$7,500
New from Oris is the Divers Sixty-Five Chronograph 40mm, which takes one of the brand's most exciting releases to a new level. Sporting a fresh sunray silver-grey dial and contrasting dark green counters, the Divers Sixty-Five Chronograph 40mm is a lovely blend of nostalgic design and modern finishings. I'm a big fan of the slight-vintage touches, in particular the use of the pump pushers, which give a more tactile and robust feel.
The case is constructed from a multi-piece stainless steel design and features sapphire, domed on both sides. You'll also find applied indices and hands are filled with Super-LumiNova for legibility, which pair tremendously well with the contrasting sub-dials for running seconds and a 30-minute counter.
Inside, the Divers Sixty-Five Chronograph 40mm is powered by the Oris Calibre 771, which is based on the workhorse Sellita SW 510 and dishes up a stellar 62 hours of power reserve. This is an all-purpose no-frills movement that well befits Oris' newest chronograph.
Blancpain Fifty Fathoms Tech 45 | Image: Blancpain
Blancpain Fifty Fathoms Tech 45
Brand: Blancpain
Blancpain Model: Fifty Fathoms Tech 45
Fifty Fathoms Tech 45 Reference: Ref. 5029 12B30 94A
Ref. 5029 12B30 94A Diameter: 45mm
45mm Thickness: 14.10mm
14.10mm Material : Titanium
: Titanium Movement: Calibre 1315A
Calibre 1315A Power Reserve: 62 hours
62 hours Price: AUD$34,000
This week, Blancpain unveiled a fresh new take on one of its best-loved timepieces, reinvigorating the Fifty Fathoms Tech 45 collection. About as extreme as a dive watch can get, the Fifty Fathoms Tech 45 is Blancpain through and through; best characterised by its titanium case, which sports satin-finishing throughout, and a water resistance rating of 300 metres.
The dial of the Fifty Fathoms Tech 45 is incredible and super noteworthy. So-called 'Absolute Black,' the dial is made to absorb 97 per cent of light, an astounding figure made that much cooler by the pops of orange on the seconds hand and 'TECH' inscription. You'll also spy a unidirectional 120-click ceramic bezel, designed for use while wearing gloves, reinforcing the utilitarian nature of the timepiece.
Importantly, the latest 45mm edition, which follows the previous Tech Gombessa and Ocean Commitment IV Tech models, marks a bold new approach. Unlike those previous iterations, the Fifty Fathoms Tech 45 is not a limited edition, meaning that it will feature prominently as part of the maison's permanent collection.
A. Lange & Söhne Zeitwerk Date | Image:A. Lange & Söhne
Brand: A. Lange & Söhne
A. Lange & Söhne Model: Zeitwerk Date
Zeitwerk Date Reference: 148.033
148.033 Diameter: 44.20mm
44.20mm Thickness: 12.30mm
12.30mm Material : Pink gold
: Pink gold Movement: Calibre L043.8
Calibre L043.8 Power Reserve: 72 hours
72 hours Price: On request
A. Lange & Söhne's Zeitwerk Date has always been a showstopper for watch fans, appearing at the very top of several 'grail watch' lists, but in 2025, the maison has reimagined the design. The latest iteration has received a new pink gold case, enhancing an aesthetic that was already as appealing as it was beautiful. The Zeitwerk Date is an extension of the ever-popular original Zeitwerk, a truly game-changing piece for the watchmaker.
Aside from the stunning new case material, the A. Lange & Söhne Zeitwerk Date also sports one of the most impressive and coveted movements in watchmaking. The in-house Calibre L043.8 is a manual-winding movement that offers a power reserve of 72 hours and is adorned with a remontoir bridge and twin mainspring barrel. This unique combination, which is undeniably A. Lange & Söhne, ensures that the right amount of power is uniformly released every 60 seconds to jump the disks.
With the Zeitwerk Date you have the digital jumping hour and minutes display, along with a peripheral date ring display set against a lovely solid silver dial with a grey finish. The cherry on top is the pink gold case. Just incredible.
Bulgari Octo Finissimo Perpetual Calendar Rose Gold | Image: Bulgari
Bulgari Octo Finissimo Perpetual Calendar Rose Gold
Brand: Bulgari
Bulgari Model: Octo Finissimo Perpetual Calendar Rose Gold
Octo Finissimo Perpetual Calendar Rose Gold Reference: 104175
104175 Diameter: 40mm
40mm Thickness: 5.80mm
5.80mm Material : Rose gold
: Rose gold Movement: Calibre BVL 305
Calibre BVL 305 Power Reserve: 60 hours
60 hours Price: €98,000
Bulgari closes off the week with a rose-gold variation of its Octo Finissimo Perpetual Calendar. It's important to note that the Octo Finissimo Perpetual Calendar is actually the world's thinnest perpetual calendar and was initially released in titanium.
Its thinness is thanks to the 2.75mm thick perpetual calendar calibre, and with a total height of only 5.80mm the Octo Finissimo Perpetual Calendar is truly a sight to behold. Let's not forget that this is also an automatic movement with a retrograde date. Wild stuff.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
United States Epilepsy Drugs Market Trends and Company Analysis Report 2025-2033 Featuring Eisai, UCB, H. Lundbeck, GW Pharmaceuticals, Abbott, Alkem Laboratories, Bausch Health, GSK
The United States Epilepsy Drugs Market is projected to grow from US$ 2.36 billion in 2024 to US$ 3.45 billion by 2033, marking a CAGR of 4.31% from 2025 to 2033. This growth is fueled by the rising prevalence of epilepsy, affecting over 3.4 million Americans, and advancements in drug development. Key players like Eisai, UCB, and Lundbeck emphasize second and third-generation AEDs offering improved safety and efficacy. Despite challenges like high treatment costs and regulatory hurdles, the market benefits from supportive FDA policies. Segmentation includes first, second, and third-generation drugs across various seizures and distribution channels. U.S. Epilepsy Drugs Market Dublin, Aug. 12, 2025 (GLOBE NEWSWIRE) -- The "United States Epilepsy Drugs Market - Therapeutic Landscape & Forecast 2025-2033" report has been added to States Epilepsy Drugs Market is expected to reach US$ 3.45 billion by 2033 from US$ 2.36 billion in 2024, with a CAGR of 4.31% from 2025 to 2033 In order to satisfy shifting customer needs, firms are being prompted by this transition to innovate and diversify their product lines. All things considered, the market for French-flavored milk is expected to grow further due to innovation, custom, and customer preferences. The market for epilepsy medications in the United States is a vibrant area of the larger neurology therapeutics business, with a wide range of antiepileptic medications (AEDs) that target different kinds of seizures. North America accounted for the greatest portion of the worldwide market for epilepsy medications in 2024, with the United States leading the way in terms of market size and revenue production. Due to their enhanced safety profiles and effectiveness, second-generation AEDs are growing at the quickest rate in the market, which is divided into first, second, and third-generation AEDs. The high demand for efficient treatment solutions is shown by the estimated 1.2% prevalence of epilepsy in the United prevalence of epilepsy has increased in the U.S. population. The seizures Foundation estimates that more than 3.4 million Americans suffer from seizures. Furthermore, 1 in 26 Americans are predicted to receive a diagnosis of epilepsy at some point in their lives, with over 150,000 receiving a diagnosis each year. New developments in medication development have accelerated the market's growth even further. The FDA's 2022 approval of ganaxolone (Ztalmy) for the treatment of seizures linked to CDKL5 deficient condition was a noteworthy milestone that provided a new therapeutic option for a patient population that had previously been underserved. Furthermore, the growing investment in specialist epilepsy medicines is demonstrated by Lundbeck's $2.6 billion acquisition of Longboard Pharmaceuticals in 2024, which was intended to develop bexicaserin for the treatment of developmental and epileptic encephalopathies. These advancements are in line with the demand for treatments that target complicated and uncommon epilepsy disorders as well as the increased emphasis on customized Factors Driving the United States Epilepsy Drugs Market Growth Increasing Prevalence of EpilepsyOne of the main factors propelling market growth is the increasing prevalence of epilepsy in the United States. It affects around 2.9 million individuals who are 18 years of age or older, with a significant incidence in youngsters. The need for efficient anti-epileptic medications (AEDs) is increased by this expanding patient base. Certain demographics, such as those from minority racial and ethnic groups and those with lower educational attainment, are more likely to have the syndrome. As more people look for medical intervention and treatment alternatives, the market is growing as a result of growing awareness and diagnosis of epilepsy. In order to satisfy the needs of a varied patient population, this trend emphasizes the necessity of ongoing innovation and accessibility in the creation and distribution of in Drug DevelopmentSecond and third-generation anti-epileptic medications (AEDs), which have better effectiveness and safety profiles, have been introduced as a result of ongoing research and development efforts. These more recent drugs aim to overcome the drawbacks of previous therapies by improving seizure control while reducing adverse effects. These developments not only improve patient outcomes but also provide medical professionals more treatment alternatives. The dedication to meeting the unmet requirements of the epilepsy community is seen in the ongoing pipeline of new AEDs, which propels market Regulatory EnvironmentFaster access to new medicines is made possible by the U.S. Food and Drug Administration's (FDA) accelerated approval of innovative anti-epileptic medications (AEDs). Pharmaceutical firms are encouraged to invest in the discovery of novel medicines by this regulatory assistance. Furthermore, programs like the Epilepsy Foundation's #RemoveTheFilter and National Epilepsy Awareness Month have raised public awareness and decreased stigma, which has encouraged more people to seek treatment. Because of these initiatives, the patient population is more informed, which increases the likelihood of diagnoses and treatment compliance. The market for epilepsy medications is expected to develop in a favorable environment because to a mix of supportive regulatory frameworks and increased public in the United States Epilepsy Drugs Market High Treatment Costs and Affordability IssuesAccess to therapy is severely hampered by the rising costs of antiepileptic medications (AEDs) in the US. For example, generic drugs are frequently less expensive than name-brand ones, such as Fycompa and Aptiom, which may cost thousands of dollars a month. Generics are not always readily available, and some more recent AEDs do not have generic counterparts, which keeps their prices high. Furthermore, insurance coverage might vary; Medicare seniors are frequently not eligible for co-pay assistance programs, and other plans have hefty deductibles or co-pays. These monetary difficulties may cause patients to stop taking their medications, which raises the risk of seizures and related problems. In order to provide fair access to efficient epilepsy therapies, it is imperative that these economic concerns be Hurdles and Market Entry DelaysNew antiepileptic medications (AEDs) must pass rigorous regulatory criteria enforced by the U.S. Food and Drug Administration (FDA), which include thorough documentation and lengthy clinical studies. For pharmaceutical firms, this stringent procedure may raise development costs and postpone the release of new medications. Furthermore, generic versions of important AEDs are introduced when their patents expire; although they are less expensive, they might not always satisfy the unique demands of every patient. People who need specialized care may have fewer alternatives due to these market factors. Additionally, market access and the profitability of AED development initiatives may be hampered by the drawn-out and expensive approval procedures linked to regulatory obstacles. Company Analysis: Overview, Key Persons, Recent Developments, Revenue Analysis Eisai Co., Ltd. UCB Inc. H. Lundbeck A/S GW Pharmaceuticals Plc. Abbott Laboratories Alkem Laboratories Limited Bausch Health Companies Inc. GSK plc Key Attributes: Report Attribute Details No. of Pages 200 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $2.36 Billion Forecasted Market Value (USD) by 2033 $3.45 Billion Compound Annual Growth Rate 4.3% Regions Covered United States Key Topics Covered: 1. Introduction2. Research & Methodology2.1 Data Source2.2 Research Approach2.3 Forecast Projection Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. Exploring the Disease - Background and Key Insights5.1 Introduction5.2 Causes5.3 Classification of Epilepsies5.3.1 West Syndrome5.3.2 Dravet syndrome5.3.3 Lennox-Gastaut syndrome5.3.4 Landau-Kleffner syndrome5.3.5 Epilepsy with continuous spike-and-waves during slow-wave sleep (ECSWS)5.3.6 CDKL5 deficiency disorder (CDD)5.4 Risk Factors5.5 Pathophysiology5.6 Diagnosis5.6.1 Diagnostic Guidelines5.6.1.1 NICE: Epilepsies in Children, Young People, and Adults (2022)5.6.1.2 American Family Physician: Diagnostic Evaluation (2017)5.6.1.3 The French National Authority for Health (HAS): 20205.6.1.4 German Society for Neurology (DGN) Guidelines: Diagnostics and Therapy in Neurology (2023)5.7 Treatment5.7.1 Antiepileptic Medications (AEDs)5.7.2 Receptor Blockers5.7.3 Others5.7.4 Diet Therapy5.7.5 Surgery5.7.5.1 Phase I Evaluation (Noninvasive Tests)5.7.5.2 Phase II Evaluation (Invasive Mon)5.7.6 Treatment Algorithm for Medical Condition5.7.7 Treatment Guidelines5.7.7.1 American Epilepsy Society5.7.7.2 American Family Physician - Epilepsy Treatment Options (2017)5.7.7.3 The International League against Epilepsy (ILAE) Epilepsy Guidelines5.7.7.4 NICE Guidelines: (2022)5.7.8 Living and Coping with Epilepsy6. United States Epilepsy Drugs Market6.1 Historical Market Trends6.2 Market Forecast7. Market Share Analysis7.1 By Drugs Category7.2 By Seizure types7.3 By Distribution Channels8. Drugs Category8.1 First Generation Drugs8.2 Second Generation Drugs8.3 Third Generation Drugs9. Seizure Types9.1 Focal Seizures9.2 Generalized Seizures9.3 Non-Epileptic Seizures10. Distribution Channels10.1 Hospital Pharmacies10.2 Drug Stores and Retail Pharmacies10.3 Online Providers11. Porter's Five Forces Analysis11.1 Bargaining Power of Buyers11.2 Bargaining Power of Suppliers11.3 Degree of Rivalry11.4 Threat of New Entrants11.5 Threat of Substitutes12. SWOT Analysis12.1 Strength12.2 Weakness12.3 Opportunity12.4 Threat13. Analysis of Marketed Medications/Drugs13.1 Key Players13.2 EPIDIOLEX/EPIDYOLEX (cannabidiol) - Jazz Pharmaceuticals13.2.1 Description of Drugs13.2.2 Regulatory Milestones13.2.3 Clinical Development Process13.2.4 Safety and Efficacy13.3 XCOPRI/ONTOZRY(cenobamate) - SK Biopharmaceutical/ Pharma/Ono Pharmaceutical13.4 FINTEPLA (fenfluramine) - UCB/Nippon Shinyaku13.5 NAYZILAM (midazolam) nasal spray - UCB Pharma13.6 VALTOCO (diazepam nasal spray) - Neurelis/Aculys Pharma13.7 ZTALMY (ganaxolone) - Marinus Pharmaceuticals/Ovid Therapeutics/Orion13.8 BRIVIACT/NUBRIVEO (brivaracetam) - UCB Pharma13.9 FYCOMPA (perampanel) - Eisai/Catalyst Pharmaceutical13.10 OXTELLAR XR (oxcarbazepine) - Supernus Pharmaceuticals13.11 VIMPAT (lacosamide) - UCB Pharma/Daiichi Sankyo14. Analysis of Emerging Drugs14.1 Key Cross Competition14.2 XEN1101 - Xenon Pharmaceuticals14.2.1 Description of Drug14.2.2 Clinical Research & Development14.2.3 Safety and efficacy14.3 LIBERVANT (diazepam buccal film) - Aquestive Therapeutics/Atnahs Pharma (Pharmanovia)14.4 Soticlestat (TAK-935) - Takeda/Ovid Therapeutics14.5 COMFYDE (carisbamate) - SK Biopharmaceuticals (SK Life Science)14.6 BHV-7000 (KB-3061) - Biohaven Pharmaceuticals/Knopp Biosciences14.7 STACCATO alprazolam (benzodiazepine) - UCB Pharma/Alexza Pharmaceuticals14.8 NBI-827104 (ACT-709478) - Neurocrine Biosciences/Idorsia Pharmaceuticals14.9 Ivermectin (EQU-001) - Equilibre Biopharmaceuticals15. Regulations and Reimbursement Policies16. Key Players Analysis For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment U.S. Epilepsy Drugs Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21 minutes ago
- Yahoo
Spirit Airlines raises going-concern doubts, months after exiting bankruptcy
(Reuters) -Spirit Airlines has warned of going-concern doubts, just months after emerging from bankruptcy as weak domestic demand and dwindling cash reserves strain its operations. Adverse market conditions such as elevated domestic capacity and weak demand for leisure travel in the second quarter has resulted in a tough pricing environment for airline, it said in its quarterly report on Monday. The company expects these pressures to persist through the rest of the year, adding to operational uncertainty. Last month, Spirit said it would furlough about 270 pilots, while demoting another 140, to conserve cash. The Florida-based airline, known for its bright yellow livery, had filed for bankruptcy protection last November, after years of losses, failed merger attempts and heavy debt. It was the first major U.S. carrier to file for Chapter 11 since 2011. It emerged from bankruptcy in March after a court approved restructuring backed by its creditors. Uncertainty stemming from President Donald Trump's sweeping tariffs and budget cuts have prompted travelers to curb spending and reassess plans. The airline said on Monday that its credit-card processor has asked it to set aside more funds as collateral or risk losing its contract, which is set to expire on Dec. 31. To address the concerns, Spirit said it plans to bolster liquidity by selling or monetizing aircraft and real estate and shedding excess airport gate capacity. Uncertainty over meeting minimum liquidity covenants and the outcome of talks with stakeholders have raised substantial doubt about the company's ability to continue as a going concern over the next 12 months, it said. 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
Yahoo
21 minutes ago
- Yahoo
Universal credit claimants hit record high of eight million people
The number of people claiming universal credit (UC) has hit a record high of eight million. Claimants jumped by more than a million in a year – from 6.9 million people in July last year. The latest figure of 8.0 million for July 2025 is the highest level it has been since UC was introduced in 2013, according to official figures published on Tuesday. UC is a payment to help with living costs and is available for people in work who are on low incomes, as well as those who are out of work or cannot work. The steep rise in the past year has been driven almost entirely by people who are not required to work, with 3.7 million in this category in July – a rise of 39% or 1 million since the same time in 2024. People in this bracket can include those in full-time education, over the state pension age, someone with a child aged under one, and those considered to have no prospect of work. The Labour Government has previously said it 'inherited a broken welfare system and spiralling, unsustainable benefits bill' from the Conservatives, and is working on reforms including tightening rules on who can claim UC. The number of working people on UC rose to 2.2 million in July, up slightly from 2.1 million 12 months previously.
